SCPS Program Committee would like to thank all of our speakers, exhibitors, and attendees
for making this a successful event!
Psychopharmacology Update 21
for making this a successful event!
Psychopharmacology Update 21
-
Saturday, January 30, 2010
The Olympic Collection
11301 Olympic Blvd.
Los Angeles, CA 90064
310-575-4585
8:30 a.m - Registration, Continental Breakfast, Booth Exhibits
8:55 a.m. - Opening Remarks
9:00 a.m. - Generic Drugs: Good Values or Bad Bargains?
James W. Jefferson, M.D., Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health and Distinguished Senior Scientist Madison Institute of Medicine.
The Federal Drug Price Competition and Patent Term Restoration Act of 1984 opened the floodgates to generic drugs by removing requirements for independently establishing efficacy and safety, and by basing approval on bioequivalence. The process required to establish bioequivalence will be discussed, as well as related relevant terms and concepts. The pros and cons of generic prescribing will be discussed and illustrated by examples involving antidepressants.
10:00 a.m. - Managing Depression During Pregnancy: Latest Consensus Findings and Guidelines
Vivien Burt, M.D., Ph.D., Professor Emeritus of Psychiatry, UCLA; Founder/Director, The Women’s Life Center, UCLA.
Between 14% and 23% of pregnant women will experience a depressive disorder while pregnant. In 2003, about 13% of women took an antidepressant at some point during pregnancy, double the rate since 1999. In order to provide full and comprehensive care that maximizes safety for mothers and their babies, it is thus relevant and important for clinicians to know and understand the information on the treatment of perinatal depression. The latest literature on fetal and neonatal outcomes associated with depression and antidepressant treatment during pregnancy will be reviewed. Research findings, guidelines and algorithms for preconception and antenatal management will be presented and discussed.
11:00 a.m. - Break
11:15 a.m. - An Evidence Based "How to Guide" for Antidepressant Augmentation Strategies
David L. Fogelson, M.D., Clinical Professor of Psychiatry, UCLA Department of Psychiatry and Biobehavioral Sciences.
When a patient does not respond to an adequate trial of an antidepressant, how do you decide what to use for augmentation? What do the most current treatment algorithms recommend? We will review combinations of antidepressants, buspirone, T3, lithium, lamotrigine, atypical antipsychotics, pindolol, psychostimulants, nutraceuticals, benzodiazepines, and psychotherapy as strategies for antidepressant augmentation.
12:15 p.m. - Lunch (lunch will not be provided.)
1:30 p.m. - Problematic Hypersexuality: Diagnosis and Treatment
John Sealy, M.D., Assistant Clinical Professor of Psychiatry UCLA School of Medicine.
Problematic hypersexuality, often referred to as sexual addiction, is an increasingly common behavior complaint across a broad age span. Although this disorder remains on the frontier of psychiatry, guidelines for diagnosis, comorbidities, consequences and treatment will be discussed to help clinicians make effective interventions. Problematic Hypersexuality, often referred to as sexual addiction, is an increasingly more common behavior complaint from patients, including adolescents. The consequences can be devastating for the patient and those who love him or her. Alhtough this disorder remains on the frontier of psychiatry, guidelines for diagnosis, comorbidities, consequences and treatment will be discussed to hep clinicians make effedtive interventions.
2:30 p.m. - Performance Enhancing Drugs: from High School to the Olympic Games
Don H. Catlin, M.D.,UCLA Professor of Molecular and Medical Pharmacology, Emeritus CEO, Anti- Doping Research.
Sport has been coping with drugs and sport for fifty years. The presentation will explain the type of drugs that are used, and comment on questions such as: How pervasive are they? Do they really enhance performance? Why do athletes continue to use them? How effective are the testing schemes? The presentation will also offer a brief overview of the use of performance enhancing drugs in school and the work place as well as reflection on the social and cultural implications of performance enhancing drugs in general.
SCPS Member $150
Non-SCPS Member $175
SCPS Resident* $10
Non-SCPS Resident* $20
*Must be enrolled in a full-time, degree granting program. Must send photocopy of student I.D. to SCPS with order form. (No exceptions.)
Printable Brochure - .pdf
Please make checks payable to:
SCPS
2999 Overland Ave. #208
Los Angeles, CA 90064
Cancellations must be received 48 hours prior to the meeting, and will be assessed a $45 administrative processing fee.
The Southern California Psychiatric Society (SCPS) is accredited by the Institute of Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians. SCPS takes responsibility for the content, quality and scientific integrity of this CME activity.
SCPS designates this educational activity for a maximum of 5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.
To order cds/tapes from events prior to 2009, please contact us at scps2999@earthlink.net
